A recent report using 17 primary serous ovarian cancer patients and in vitro models showed that EZH2 loss drives resistance to carboplatin and paclitaxel in serous ovarian cancers that express Ataxia Telangiectasia Mutated (ATM) [148]. Here, ATM is linked to ovarian serous adenocarcinoma.